Sona Nanotech Inc C.SONA

Alternate Symbol(s): SNANF

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.

CSE:SONA - Post by User

Sona Nanotech Inc > We lost our focus

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Nov 28, 2020 2:33pm

184 Views

Post# 31995042

RE:We lost our focus

I'll try it.

oxinos wrote: A while back we were so excited about the gold nanorod technology and it's unlimited uses in the health sciences. But we were focused exclusively on one thing. On Sona's lateral flow antigen test and when we met road blocks on the way to approval from FDA and HC our world fell apart as if all other prospects of the patent application for the gold nanorod technology and it's many uses did not exist anymore.

The sell off for this temporary delay was immense. The lateral flow antigen test was the tree that blocked our view of the forest, (the many uses of the nanorod technology), was all but forgotten.

We need to pull back from the antigen test tree so that we can see the forest. The company still has the CTAB free nanorod technology that can be used in drug delivery for targeted cancer treatment and host of other uses that has the potential to change the methods of treatments.

When someone trips up and falls to the ground does he stay down? No. He gets back up. That is how it will be for Sona. The company stumbled in its quest for approval of its lateral flow antigen test. They didn't give up. It will take a little while longer.

The value in this company is not the antigen test but the disruptive technology that it has and the variety of uses that it can applied to.